ICU Medical (ICUI) FY2017 results: revenue $1.3 billion, up 240.7% on the year
ICU Medical Inc. (ICUI) reported revenue of $1.3 billion for fiscal 2017, the year ended 31 December 2017, up 240.7% on the year before. Net income was $69 million, up 8.8%, and diluted earnings per share $3.29. The figures are the company's own, from the 10-K it filed with the SEC on 16 March 2018.
Revenue
$1.3 billion
+240.7% on the year
FY2010FY2017
Operating margin
-1.0%
21.9% a year earlier
FY2010FY2017
Net income
$69 million
+8.8% on the year
FY2010FY2017
Diluted EPS
$3.29
-10.1% on the year
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
1,293
379
342
+240.7%
Cost of revenue
867
178
161
+386.9%
Gross profit
426
201
181
+111.6%
Gross margin
33.0%
53.1%
52.9%
Research and development
51.3
13.0
15.7
+295.6%
Selling, general and administrative
302
89.4
83.2
+237.9%
Operating income
-13.3
82.9
68.6
Operating margin
-1.0%
21.9%
20.1%
Interest expense
2.0
0.1
0.0
+1,634.7%
Pre-tax income
51.3
85.2
69.7
-39.8%
Income tax
-17.4
22.1
24.7
Effective tax rate
-33.9%
25.9%
35.5%
Net income
68.6
63.1
45.0
+8.8%
Net margin
5.3%
16.6%
13.2%
Diluted EPS
$3.29
$3.66
$2.73
-10.1%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
154
89.9
64.2
+71.7%
Capital expenditure
74.5
23.4
13.0
+218.8%
Free cash flow
79.9
66.6
51.2
+20.1%
Free cash flow margin
6.2%
17.6%
15.0%
Cash from investing
-267
16.3
-11.2
Cash from financing
-44.3
2.5
15.7
Depreciation and amortisation
66.6
19.1
18.1
+249.4%
Share-based compensation
19.4
15.2
12.8
+27.0%
Buybacks
4.1
17.2
1.5
-76.5%
Diluted shares, weighted
21m
17m
16m
+20.9%
Shares outstanding at period end
20m
16m
16m
+23.7%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
1,198
660
580
+81.5%
Debt
n/a
0.0
0.0
Other liabilities
299
44.5
47.0
+570.7%
Total liabilities and equity
1,497
705
627
+112.4%
Fixed assets
399
85.7
74.3
+365.2%
Goodwill
12.4
5.6
6.5
+121.6%
Intangible assets
144
22.4
23.9
+542.2%
Investments
24.6
0.0
41.2
Cash and equivalents
290
445
336
-34.8%
Receivables
113
56.2
57.8
+100.7%
Inventory
289
49.3
43.6
+485.9%
Other assets
226
40.5
43.2
+457.9%
Total assets
1,497
705
627
+112.4%
10-K for the year ended 31 December 2017, filed 16 March 2018: the filing.